Harvard study links Novo's Ozempic to increased risk of vision loss

A Harvard University study has found an association between Novo Nordisk's Ozempic and an elevated risk of vision loss, prompting calls for updated safety warnings. The finding is based on observational data and causality is not yet established. This could affect regulatory scrutiny and prescribing practices for GLP-1 medications.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works